当前位置：
X-MOL 学术
›
Cancer Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Cancer Medicine ( IF 2.9 ) Pub Date : 2019-12-26 , DOI: 10.1002/cam4.2791 Yang Liu 1, 2 , Yinping Dong 3 , Hui Zhu 2 , Wang Jing 2 , Hongbo Guo 4 , Jinming Yu 2
Cancer Medicine ( IF 2.9 ) Pub Date : 2019-12-26 , DOI: 10.1002/cam4.2791 Yang Liu 1, 2 , Yinping Dong 3 , Hui Zhu 2 , Wang Jing 2 , Hongbo Guo 4 , Jinming Yu 2
Affiliation
|
PURPOSE
This study aimed to assess the effect of nanoparticle albumin-bound paclitaxel (nab-PTX) chemotherapy regimens in elderly patients (≥70 years old) with advanced squamous non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS
The clinical records of elderly patients aged ≥70 years with advanced squamous NSCLC were reviewed retrospectively. All of these patients received nab-PTX, with or without combination of chemotherapy in Shandong Cancer Hospital and Institute between 1 July 2012 and 30 June 2017. We analyzed the toxicity profiles, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR).
RESULTS
Totally, 52 elderly patients with squamous NSCLC were included in the analysis. For all patients, the ORR was 34.6%, the DCR was 80.8%, median PFS was 5.9 months (95% confidence interval [CI]: 4.0-7.8 months), and median OS was 14.3 months (95% CI: 11.0-17.8 months). Combination with chemotherapy significantly prolonged OS (19.3 vs 11.2 months, P = .016), despite a nonsignificant improvement in PFS (7.1 vs 4.2 months, P = .060) vs monotherapy. For patients who received nab-PTX as first-line treatment, the median PFS and OS were 6.7 months and 17.2 months, respectively, and the median OS in combination therapy subgroup was significantly higher than that in monotherapy group (20.3 vs 11.2 months, P = .013). Meanwhile, the median PFS and OS of patients with nab-PTX as second- or later-line treatment were 4.4 months and 13.3 months, respectively, but no survival benefit was achieved by the combination chemotherapy when compared with single-agent chemotherapy. Hematologic toxicities were the most common adverse events (AEs), which include grade 3 or 4 neutropenia (13.7%), thrombocytopenia (4.1%), and anemia (6.8%). The main nonhematologic toxicities were peripheral sensory neuropathy (39.7%), followed by anorexia and nausea/vomiting.
CONCLUSION
In elderly advanced squamous NSCLC patients, the treatment of nab-PTX was effective and well tolerated.
中文翻译：
纳米颗粒白蛋白结合紫杉醇在老年晚期鳞状非小细胞肺癌患者中的回顾性研究。
目的本研究旨在评估纳米白蛋白结合紫杉醇（nab-PTX）化疗方案对老年晚期鳞状非小细胞肺癌（NSCLC）患者（≥70岁）的作用。方法回顾性分析≥70岁老年晚期鳞状NSCLC患者的临床资料。在2012年7月1日至2017年6月30日之间，所有这些患者在山东省肿瘤医院和研究所接受了nab-PTX联合或不联合化疗。我们分析了毒性特征，无进展生存期（PFS），总生存期（OS），客观反应率（ORR）和疾病控制率（DCR）。结果总共纳入了52例老年鳞状NSCLC患者。所有患者的ORR为34.6％，DCR为80.8％，中位PFS为5。9个月（95％可信区间[CI]：4.0-7.8个月），中位OS为14.3个月（95％CI：11.0-17.8个月）。尽管与单药治疗相比，PFS无显着改善（7.1 vs 4.2个月，P = .060），但联合化疗显着延长了OS（19.3 vs 11.2个月，P = .016）。对于接受nab-PTX一线治疗的患者，中位PFS和OS分别为6.7个月和17.2个月，联合治疗亚组的OS的中位数显着高于单药治疗组（20.3 vs 11.2个月，P = .013）。同时，接受nab-PTX作为二线或后线治疗的患者的中位PFS和OS分别为4.4个月和13.3个月，但与单药化疗相比，联合化疗无法获得生存获益。血液学毒性是最常见的不良事件（AE），包括3级或4级中性粒细胞减少症（13.7％），血小板减少症（4.1％）和贫血（6.8％）。主要的非血液学毒性是周围感觉神经病（39.7％），其次是厌食和恶心/呕吐。结论在老年晚期鳞状NSCLC患者中，nab-PTX的治疗有效且耐受性良好。
更新日期：2019-12-27
中文翻译：
纳米颗粒白蛋白结合紫杉醇在老年晚期鳞状非小细胞肺癌患者中的回顾性研究。
目的本研究旨在评估纳米白蛋白结合紫杉醇（nab-PTX）化疗方案对老年晚期鳞状非小细胞肺癌（NSCLC）患者（≥70岁）的作用。方法回顾性分析≥70岁老年晚期鳞状NSCLC患者的临床资料。在2012年7月1日至2017年6月30日之间，所有这些患者在山东省肿瘤医院和研究所接受了nab-PTX联合或不联合化疗。我们分析了毒性特征，无进展生存期（PFS），总生存期（OS），客观反应率（ORR）和疾病控制率（DCR）。结果总共纳入了52例老年鳞状NSCLC患者。所有患者的ORR为34.6％，DCR为80.8％，中位PFS为5。9个月（95％可信区间[CI]：4.0-7.8个月），中位OS为14.3个月（95％CI：11.0-17.8个月）。尽管与单药治疗相比，PFS无显着改善（7.1 vs 4.2个月，P = .060），但联合化疗显着延长了OS（19.3 vs 11.2个月，P = .016）。对于接受nab-PTX一线治疗的患者，中位PFS和OS分别为6.7个月和17.2个月，联合治疗亚组的OS的中位数显着高于单药治疗组（20.3 vs 11.2个月，P = .013）。同时，接受nab-PTX作为二线或后线治疗的患者的中位PFS和OS分别为4.4个月和13.3个月，但与单药化疗相比，联合化疗无法获得生存获益。血液学毒性是最常见的不良事件（AE），包括3级或4级中性粒细胞减少症（13.7％），血小板减少症（4.1％）和贫血（6.8％）。主要的非血液学毒性是周围感觉神经病（39.7％），其次是厌食和恶心/呕吐。结论在老年晚期鳞状NSCLC患者中，nab-PTX的治疗有效且耐受性良好。
京公网安备 11010802027423号